



## Annual Meeting 2023

November 19th,  
Kastrup, Copenhagen 10:30-15.30

### Minutes of Meeting:

1. **Welcome** Helle Thiesson

2. **Writer of minutes** Ida Maria Schmidt

3. **Minutes from the last** meeting were approved.

4. **Presentation of participants**

- A list of meeting participants is found at the end of these minutes
- Mailing list updated: country representatives are responsible for keeping the list updated.

5. **All key persons were reelected.**

- Helle Thiesson (DK)
- Inga Vainumäe (EST)
- Timo Jahnuainen (FIN)
- Vidar Örn Edverdsson (ISL)
- Ann Christin Gjerstad (NOR)
- Lars Wennberg (SWE)
- Søren Schwartz Sørensen (NKG)

6. **Annual report (Søren Schwartz Sørensen, Denmark):**

The report will soon be available on the Scandiatransplant website: <https://www.scandiatransplant.org/members/nkg/nprtsg>

The age cutoff for pediatric patients has been updated from 16 to 18 years.

## **7. NPRTSG History (1994-2024) (Søren Schwartz Sørensen, Denmark):**

NPRTSG was founded in 1994 by Ulla Berg and Gunnar Tydén. The first meeting was held on April 15, 1994. The objective was: to establish a standalone database, annual reporting, and meetings. Participants included all healthcare professionals in the field of pediatric renal transplantation.

**2010:** Database merged with ScandiTransplant database (YASWA).

**2016:** NPRTSG became a subgroup under the Nordic Kidney Group within ScandiTransplant. Publications: Numerous publications have been produced.

## **8. Status on ERN TransplantChild and PETER Register (Lars Wennberg online):**

A subgroup within the ERN Transplant Child initiative. Working groups are active at the EU level. In Stockholm, they focus on WP7: Educational material and guidelines for pets, vaccinations, CMV, FSG recurrence, and minimizing immunosuppression.

PETER: Includes all transplants, including bone marrow. Goal: to include 40% of all transplants using PedsQL.

Discussion about the lack of cooperation among different EU registries under ERN.

Consent is mandatory but varies between Nordic countries.

## **9. Risk and prognosis of post-transplant lymphoproliferative disease in Epstein-Barr virus - seronegative kidney transplant recipients (pediatric and adult) - An observational cohort study from Norway and Western Denmark (Lene Ugilt P. Ludvigsen, Denmark):**

Three different classifications were reviewed. PTLD incidence:

14% in high-risk children.

7% in high-risk adults.

Rituximab appears to protect against PTLD, while basiliximab seems to increase the risk.

## **10. PTLD status and future project in NPRTSG (Ann Christin Gjerstad, Norway). Study proposals and ideas were discussed.**

## **11, 13. Association of HLA B and T cell molecular mismatches with HLA antibodies, rejection and graft survival in pediatric kidney transplantation. The impact of reduced immunosuppression on alloimmunity: A retrospective study of pediatric kidney transplant recipients. (AM Gramkow, Denmark)**

Annual HLA testing.

Hospitalizations, infections, and survival versus DS antibodies.

Protocol: Tacrolimus + MMF + Basiliximab.

Reasons for reduction: Leukopenia, viral infections, abdominal issues.

Indications of over-suppression: Infections, hospitalizations, and infection rates. Younger patients experience more hospitalizations and infections.

Rejection rates:

1 year: 4%.

5 years: 10%.

HLA immunization (Luminex):

De novo DSA: 11% impact on graft survival.

HLA-sensitized: 60% (no significant impact on organ survival). Compared to other studies, this rate is lower.

**12. Use of Imlifidase for Desensitization (Lars Wennberg, Sweden, online):**

Presentation of an ongoing study.

Patients can be included via LW.

Study involves living and deceased donors.

**14. Review of Immunosuppressive Regimens (Helle Thiesson, Denmark):**

MMF AUC target: 30-50.

Discussion on basiliximab: its effect is inconclusive.

Prednisolone: Can it be phased out? Concerns about metabolic effects, growth, infections, and cancer. The possibility of stopping steroids was discussed. ERN Transplant Child guideline on steroid tapering was mentioned.

Discussion on protocols:

Finland protocol biopsies at 3 months, 18 months, and 3 years.

DSA measured once a year.

MMF-AUC: Norwegian calculator.

Next meeting: Review ERN Transplant Child's steroid protocol.

**15. Research Proposals:**

A) Randomized controlled study of Rituximab pre-transplantation in EBV seronegative patients.

B) Interaction between chronic kidney disease and psychiatric disorders:

Incidence up to 53%.

Correlation between nonadherence and psychiatric disorders.

Proposal: Study prevalence in Nordic countries, diagnostic methods, impact of psychiatric comorbidity on transplantation outcomes, long-term mental health outcomes, and management strategies.

**16. Any other business?**

Patients with Neurological Delayed Psychomotor Development:

Discussion on when to offer RRT (dialysis and transplant).

No conclusion was reached, but experiences were shared.

**17. Next Meetings:**

**2026:** Helsinki

**2025:** Sweden (Skåne), November 18th, in Kastrup

**2024:** Copenhagen

**2023:** Stockholm

**2022:** (COVID)

**2021:** Helsinki

**2020:** Oslo

**Meeting participants:**

Anne Ørskov Boserup

Ylinen Elisa

Jahnukainen Timo

Savonius Okko

Elisa Ylinen

Zivile Bekassy

Maria Herthelius

Tomas Lorant

Marie Tranäng

Susanne Westphal

Mia Dursun

Åse Noren

Ann Christin Gjerstad

Inga Vainumäe

Søren Rittig

Hanne Nørgaard

Line Thousig Sehested

Ida Maria Schmidt

Søren Schwatz Sørensen

Ann Maria Gramkow

Lene Ugilt Pagter Ludvigsen

Line aas Mortensen

Helle C Thiesson

Mette Neland

Marita Bladh (online)

Lars Wennberg (online)